[HTML][HTML] Antigenic evolution of SARS coronavirus 2
AZ Mykytyn, RAM Fouchier, BL Haagmans - Current Opinion in Virology, 2023 - Elsevier
SARS coronavirus 2 (SARS-CoV-2), the causative agent of COVID-19, emerged in China in
December 2019. Vaccines developed were very effective initially, however, the virus has …
December 2019. Vaccines developed were very effective initially, however, the virus has …
Antitarget, anti-SARS-CoV-2 leads, drugs, and the drug discovery–genetics alliance perspective
The most advanced antiviral molecules addressing major SARS-CoV-2 targets (Main
protease, Spike protein, and RNA polymerase), compared with proteins of other human …
protease, Spike protein, and RNA polymerase), compared with proteins of other human …
[HTML][HTML] Neutralization of ba. 4–ba. 5, ba. 4.6, ba. 2.75. 2, bq. 1.1, and xbb. 1 with bivalent vaccine
J Zou, C Kurhade, S Patel, N Kitchin… - … England Journal of …, 2023 - Mass Medical Soc
Neutralization of BA.4–BA.5, BA.4.6, BA.2.75.2, BQ.1.1, and XBB.1 with Bivalent Vaccine | New
England Journal of Medicine Skip to main content The New England Journal of Medicine …
England Journal of Medicine Skip to main content The New England Journal of Medicine …
[HTML][HTML] Spike and nsp6 are key determinants of SARS-CoV-2 Omicron BA. 1 attenuation
Abstract The SARS-CoV-2 Omicron variant is more immune evasive and less virulent than
other major viral variants that have so far been recognized,,,,,,,,,,–. The Omicron spike (S) …
other major viral variants that have so far been recognized,,,,,,,,,,–. The Omicron spike (S) …
Development of highly potent noncovalent inhibitors of SARS-CoV-2 3CLpro
The 3C-like protease (3CLpro) is an essential enzyme for the replication of SARS-CoV-2
and other coronaviruses and thus is a target for coronavirus drug discovery. Nearly all …
and other coronaviruses and thus is a target for coronavirus drug discovery. Nearly all …
[HTML][HTML] A rapid cell-free expression and screening platform for antibody discovery
AC Hunt, B Vögeli, AO Hassan, L Guerrero… - Nature …, 2023 - nature.com
Antibody discovery is bottlenecked by the individual expression and evaluation of antigen-
specific hits. Here, we address this bottleneck by developing a workflow combining cell-free …
specific hits. Here, we address this bottleneck by developing a workflow combining cell-free …
[HTML][HTML] Host immunological responses facilitate development of SARS-CoV-2 mutations in patients receiving monoclonal antibody treatments
A Gupta, A Konnova, M Smet, M Berkell… - The Journal of …, 2023 - Am Soc Clin Investig
Background The role of host immunity in emergence of evasive SARS-CoV-2 Spike
mutations under therapeutic monoclonal antibody (mAb) pressure remains to be explored …
mutations under therapeutic monoclonal antibody (mAb) pressure remains to be explored …
[HTML][HTML] Pre-existing immunity modulates responses to mRNA boosters
Summary mRNA vaccines are effective in preventing severe COVID-19, but breakthrough
infections, emerging variants, and waning immunity warrant the use of boosters. Although …
infections, emerging variants, and waning immunity warrant the use of boosters. Although …
[HTML][HTML] Understanding mutations in human SARS-CoV-2 spike glycoprotein: a systematic review & meta-analysis
Genetic variant (s) of concern (VoC) of SARS-CoV-2 have been emerging worldwide due to
mutations in the gene encoding spike glycoprotein. We performed comprehensive analyses …
mutations in the gene encoding spike glycoprotein. We performed comprehensive analyses …
[HTML][HTML] SARS-CoV-2 Omicron boosting induces de novo B cell response in humans
The primary two-dose SARS-CoV-2 mRNA vaccine series are strongly immunogenic in
humans, but the emergence of highly infectious variants necessitated additional doses and …
humans, but the emergence of highly infectious variants necessitated additional doses and …